PLAINSBORO, N.J., Oct. 1, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has entered into a development agreement pursuant to which CNS Technology, LLC has agreed to perform a variety of development and other activities related to the CNS System for use in the neuromonitoring field.

The CNS System is a portable, computer-based system that continuously records, displays, stores and analyzes physiological data from multiple monitoring sources in real time. The data is stored on an internal computer and can be archived for later review and additional analysis. The system's display is integrated to show trends and correlations between various monitoring parameters. Protocols can be stored in the monitor that allow a user to step through a specific monitoring procedure. All of the context sensitive decision support information is embedded in the software for display at the appropriate time in the procedure.

"Integra has a long and successful history in the field of neuromonitoring with our Camino®, Ventrix®, LICOX® and soon to be introduced NeuroSensor® product lines," said Stuart M. Essig, Integra's Chief Executive Officer. "The CNS alliance will provide Integra with a valuable platform to integrate innovative, new products for measuring and recording clinically important brain parameters and trends, such as intracranial pressure, oxygen and cerebral blood flow."

Integra will record a $0.5 million research and development charge in the third quarter in connection with the agreement.

CNS Technology founders Gary Trapuzzano and Dick Moberg developed the first easy-to-use brain activity monitor, the Neurotrac, introduced in 1982 and used worldwide in anesthesia and neurocritical care. CNS Technology, largely funded by grants from the National Institutes of Health, was formed in 2002 to commercialize research and development efforts at Moberg Research, Inc.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,200 employees. Please visit our website at (http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the development, functionality and performance of the CNS System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to adopt the CNS System may affect the launch of the CNS System and the review by external auditors and regulatory agencies of our assumptions used to estimate the research and development charge may affect the charge to be recorded. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors Than May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2003 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@integra-ls.com

Maria Platsis
Director of Corporate Development
and Investor Relations
(609) 936-2333
mplatsis@integra-ls.com